Experienced in Appendix Cancer

Dr. Bhavana Konda

Oncology
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
Accepting New Patients
Offers Telehealth
Experienced in Appendix Cancer
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bhavana Konda is an Oncologist in Dublin, Ohio. Dr. Konda is rated as an Experienced provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Neuroendocrine Tumor, Thyroid Cancer, Adrenal Cancer, Liver Embolization, and Pancreaticoduodenectomy. Dr. Konda is currently accepting new patients.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017
Other Locations
OSU INTERNAL MEDICINE LLC
2050 Kenny Rd, Columbus, OH 43221

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Sorafenib, Everolimus
Study Phase: Phase 2
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
View 6 Less Clinical Trials

62 Total Publications

Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.
Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: September 02, 2025
Similar Doctors
Distinguished in Appendix Cancer
Dr. John L. Hays
Oncology
Distinguished in Appendix Cancer
Dr. John L. Hays
Oncology

Osu Internal Medicine LLC

3651 Ridge Mill Dr, 
Hilliard, OH 
 (4.8 miles away)
614-293-3873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Hays is an Oncologist in Hilliard, Ohio. Dr. Hays is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Colorectal Cancer, Ovarian Cancer, Appendix Cancer, and Familial Colorectal Cancer. Dr. Hays is currently accepting new patients.

Advanced in Appendix Cancer
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology
Advanced in Appendix Cancer
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology

Mercy Health Physicians Springfield Specialty Care LLC

900 Scioto St, Suite 1, 
Urbana, OH 
 (33.6 miles away)
937-717-4884
Languages Spoken:
English, Punjabi, Spanish
See accepted insurances
Accepting New Patients

Daljeet Singh is a Hematologist Oncology specialist and a Hematologist in Urbana, Ohio. Dr. Singh is rated as an Advanced provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Familial Colorectal Cancer, Small Lymphocytic Lymphoma (SLL), Breast Cancer, and Paget Disease of the Breast. Dr. Singh is currently accepting new patients.

Experienced in Appendix Cancer
Dr. Erin R. Macrae
Oncology
Experienced in Appendix Cancer
Dr. Erin R. Macrae
Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (3.9 miles away)
614-442-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Macrae is an Oncologist in Columbus, Ohio. Dr. Macrae is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Macrae is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Konda's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 9 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile